Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07508995 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Sep 1, 2026 to Aug 20, 2026 · Eligibility criteria expanded, about 33 words · Study description expanded, about 8 words · 1 more Show 4 more changesShow less
    • Start date changed from estimate of Sep 1, 2026 to Aug 20, 2026
    • Eligibility criteria expanded, about 33 words
    • Study description expanded, about 8 words
    • Site details revised
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label, single-arm, phase II study which will assess the safety and efficacy of BGB16673 in combination with sonrotoclax as a time-limited approach for participants with treatment-naive CLL/SLL.
Trial Details
NCT Number NCT07508995
Lead Sponsor M.D. Anderson Cancer Center
Conditions Chronic Lymphocytic Leukemia (CLL)
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov